2026 Q2 Portfolio Activity
In 2026 Q2, Royalty Pharma Sub-Manager, LLC maintained a portfolio of 5 distinct positions. The most significant new addition was KAILERA THERAPEUTICS, now representing 22.36% of the total fund value. They heavily accumulated shares in ZENAS BIOPHARMA, INC., increasing the position by 89.1%. Conversely, Royalty Pharma Sub-Manager, LLC completely exited their position in BIOCRYST PHARMACEUTICALS INC.
Position History
hover any row below to update
Loading…
Total Positions
5
Quarter
2026 Q2
Top Holding
CYTK (34.5%)
Top 10 Concentration
100.0%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-5 of 5
Royalty Pharma Sub-Manager, LLC Full Holdings List — 2026 Q2
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
CYTK
CYTOKINETICS, I...
|
Healthcare | 34.52% | 36.36% |
#1
Prev: #1
|
7.0 |
—
|
no change | no change |
P
S
|
980,392 | $83,519,594 |
$65.91
-0.4%
|
2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
BCAX
ZENAS BIOPHARMA...
|
Healthcare | 25.05% | 26.77% |
#2
Prev: #2
|
8.5 |
—
|
1,125,000 | 89.1% |
P
S
|
2,388,150 | $60,611,247 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
N/A
KAILERA THERAPE...
|
|
Unknown | 22.36% | — |
#3
Prev: #—
|
8.5 |
—
|
2,455,357 | — |
NEW
|
2,455,357 | $54,091,515 | — | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
BHVN
BIOHAVEN LTD
|
Healthcare | 18.06% | 19.35% |
#4
1
Prev: #3
|
5.5 |
—
|
no change | no change |
P
S
|
2,936,507 | $43,695,224 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
BCRX
BIOCRYST PHARMA...
|
Healthcare | 0.00% | 17.51% |
Sold All 😨
(Was: #4) |
0.0 |
—
|
-3,846,154 | -100.0% |
CLOSED
|
— | $— | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 |
Showing 1-5 of 5 holdings